NASDAQ:AGRX - Agile Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.89 +0.11 (+14.10 %) (As of 01/18/2019 04:00 PM ET)Previous Close$0.78Today's Range$0.78 - $0.8952-Week Range$0.23 - $3.92Volume695,800 shsAverage Volume201,967 shsMarket Capitalization$26.81 millionP/E RatioN/ADividend YieldN/ABeta-0.16 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey. Receive AGRX News and Ratings via Email Sign-up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGRX Previous Symbol CUSIPN/A Webwww.agiletherapeutics.com Phone609-683-1880Debt Debt-to-Equity RatioN/A Current Ratio2.10 Quick Ratio2.10Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.06 per share Price / Book0.84Profitability EPS (Most Recent Fiscal Year)($0.91) Net Income$-28,300,000.00 Net MarginsN/A Return on Equity-78.04% Return on Assets-56.15%Miscellaneous Employees21 Outstanding Shares34,380,000Market Cap$26.81 million OptionableOptionable Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions What is Agile Therapeutics' stock symbol? Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX." How were Agile Therapeutics' earnings last quarter? Agile Therapeutics Inc (NASDAQ:AGRX) released its earnings results on Thursday, November, 1st. The specialty pharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.04. View Agile Therapeutics' Earnings History. When is Agile Therapeutics' next earnings date? Agile Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Agile Therapeutics. What price target have analysts set for AGRX? 4 brokerages have issued twelve-month target prices for Agile Therapeutics' shares. Their predictions range from $3.00 to $4.00. On average, they anticipate Agile Therapeutics' stock price to reach $3.3333 in the next twelve months. This suggests a possible upside of 274.5% from the stock's current price. View Analyst Price Targets for Agile Therapeutics. What is the consensus analysts' recommendation for Agile Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agile Therapeutics. Has Agile Therapeutics been receiving favorable news coverage? Press coverage about AGRX stock has been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Agile Therapeutics earned a news impact score of 2.0 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the near term. Are investors shorting Agile Therapeutics? Agile Therapeutics saw a decline in short interest in the month of December. As of December 14th, there was short interest totalling 1,294,868 shares, a decline of 27.0% from the November 30th total of 1,772,743 shares. Based on an average daily trading volume, of 299,140 shares, the days-to-cover ratio is currently 4.3 days. Currently, 5.5% of the shares of the company are sold short. View Agile Therapeutics' Current Options Chain. Who are some of Agile Therapeutics' key competitors? Some companies that are related to Agile Therapeutics include Generex Biotechnology (GNBT), Correvio Pharma (CORV), Evofem Biosciences (EVFM), Vernalis (VNLPY), Sierra Oncology (SRRA), Avadel Pharmaceuticals (AVDL), DURECT (DRRX), PhaseBio Pharmaceuticals (PHAS), Catalyst Biosciences (CBIO), Teligent (TLGT), VERONA PHARMA P/S (VRNA), Mustang Bio (MBIO), Cumberland Pharmaceuticals (CPIX), Chiasma (CHMA) and Mersana Therapeutics (MRSN). Who are Agile Therapeutics' key executives? Agile Therapeutics' management team includes the folowing people: Mr. Alfred F. Altomari, Chairman & CEO (Age 60)Mr. Scott M. Coiante, CFO & Sr. VP (Age 52)Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 51)Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 53)Mr. Robert G. Conway, Sr. VP of Enterprise Planning & Information Management (Age 62) Who are Agile Therapeutics' major shareholders? Agile Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.16%). Company insiders that own Agile Therapeutics stock include Alfred Altomari, Life Sciences Maste Perceptive and Renee Selman. View Institutional Ownership Trends for Agile Therapeutics. Which major investors are selling Agile Therapeutics stock? AGRX stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Agile Therapeutics. How do I buy shares of Agile Therapeutics? Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Agile Therapeutics' stock price today? One share of AGRX stock can currently be purchased for approximately $0.89. How big of a company is Agile Therapeutics? Agile Therapeutics has a market capitalization of $26.81 million. The specialty pharmaceutical company earns $-28,300,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Agile Therapeutics employs 21 workers across the globe. What is Agile Therapeutics' official website? The official website for Agile Therapeutics is http://www.agiletherapeutics.com. How can I contact Agile Therapeutics? Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected] MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 322 (Vote Outperform)Underperform Votes: 188 (Vote Underperform)Total Votes: 510MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2019 by MarketBeat.com StaffFeatured Article: What is Liquidity?